AccurEdit has built China’s first (and one of very few in the world) industry-scale, end-to-end platform for in vivo gene editing that focuses on RNA synthesis, editing and delivery technologies. This end-to-end platform enables the development of in vivo gene editing products in compliance with ICH guidelines from early stage till product approval.

The RNA technology platform enables the synthesis of mRNAs and gRNAs with high purity at research or GMP grade.

The gene editing platform has developed cutting edge editors for the modification of DNA, RNA and other genetic components. The platform also enables the design, screening, optimization and validation of gRNA aided by AccurEdit's independently-developed algorithms.

The delivery platform enables the development of LNP and polymer-based technologies targeted for liver and other organs with industry-leading efficiency and specificity.